Status:
TERMINATED
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
Lead Sponsor:
AstraZeneca
Conditions:
Thromboembolism
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a perio...
Eligibility Criteria
Inclusion
- Signed informed consent,
- Female or male aged 18 years and over
- Patient scheduled for primary elective hip replacement or patient requiring surgery for hip fracture.
Exclusion
- History of heparin-induced thrombocytopenia
- Conditions associated with increased risk of bleeding, renal impairment, known active liver disease or liver insufficiency.
- Myocardial infarction, Ischemic stroke or Transient Ischemic Attack (TIA), systemic embolism or venous thrombo-embolism within 30 days of enrollment.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
3300 Patients enrolled
Trial Details
Trial ID
NCT00206089
Start Date
September 1 2005
End Date
August 1 2006
Last Update
November 15 2010
Active Locations (125)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Graz, Austria
2
Research Site
Innsbruck, Austria
3
Research Site
Leoben, Austria
4
Research Site
Neunkirchen, Austria